Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination.

导出 OA

翻译打印收藏纠错

第一作者： Sanjiti,Podury

第一单位： Army College of Medical Sciences, India.

作者： Sanjiti,Podury ^[1] ; Erum,Khan ^[2] ; Medha,Tandon ^[3] ; Shruti,Jaiswal ^[4] ; Shitiz,Sriwastava ^[5]

作者单位： Army College of Medical Sciences, India. ^[1] B.J. Medical College and Civil Hospital, Ahmedabad, India. ^[2] University of Pittsburgh Medical Center, Pittsburgh, PA, United States. ^[3] West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States. ^[4] Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States; West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States. Electronic address: shitiz.sriwastava@hsc.wvu.edu. ^[5]

关键词 COVID-19 COVID-19 vaccine Disease modifying therapies Multiple Sclerosis

主题词人类(Humans);免疫疗法(Immunotherapy);多发性硬化(Multiple Sclerosis);接种(Vaccination)

DOI 10.1016/j.jocn.2021.05.063

PMID 34275536

发布时间 2022-12-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交